Result of AGM
RNS & Investor News
Grant of Options
27 March 2019
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to Frederic Narbel, a newly appointed Director of the Company, at an exercise price of 78.5p. Full details of the options agreement are set out below.
|Director||Number of options||Exercise price|
The options were granted with an effective date of 25 March 2019 and may be exercised up to 10 years from this date.
The options have performance criteria attached to them which includes significant revenue targets. Option holders can only purchase and/or sell shares once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to attract and retain key staff who deliver to revenue targets and build shareholder value is important to OptiBiotix's continued success. The granting of share options helps OptiBiotix compete with the remuneration packages offered by larger corporates and incentivises the team to focus both effort and activity on rapidly growing revenues and building shareholder value. These options are offered to staff and do not become exercisable (i.e. sellable) until they achieve significant revenue targets which, if achieved, will create substantive shareholder value".
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti
|Tel: 020 7213 0880|
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
|Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014|
|1||Details of the person discharging managerial responsibilities/person closely associated|
|2||Reason for notification|
|a.||Position/Status||Managing Director of Prebiotics, Director of the Company|
|b.||Initial notification/ Amendment||Initial Notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|a.||Name||OptiBiotix Health Plc|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a.||Description of the financial instrument, type of instrument
|Options over 500,000 ordinary shares of 2p each with an exercise price of 78.5p
|b.||Nature of the transaction||Award of option to purchase ordinary shares of the Company. Following the transaction, Mr Frederic Narbel has an interest in options over 500,000 ordinary shares.|
|c.||Price(s) and volume(s)|
|Price(s) per share||Volume(s)|
|d.||Date of the transaction||27 March 2019|
|e.||Place of the transaction||London Stock Exchange, AIM|
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020